ACCOUNTS - Final Accounts preparation

Registered number: 16218821

MSI PHARMA STAFFING LIMITED

UNAUDITED

FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

MSI PHARMA STAFFING LIMITED

REGISTERED NUMBER: 16218821

BALANCE SHEET

AS AT 31 MARCH 2026

		2026
Note		£

Fixed assets
Tangible assets	4		4,007
Current assets
Debtors: amounts falling due within one year	5	1,665,463
Cash at bank and in hand	6	209,892
		1,875,355
Creditors: amounts falling due within one year	7	(1,666,478)
Net current assets			208,877
Total assets less current liabilities			212,884

Net assets			212,884

Capital and reserves
Called up share capital	8	1
Profit and loss account		212,883
		212,884

Page 1

MSI PHARMA STAFFING LIMITED

REGISTERED NUMBER: 16218821

BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2026

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

N J Simpson

Director

Date: 16 October 2026

The notes on pages 3 to 8 form part of these financial statements.

Page 2

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

1.	General information

MSI Pharma Staffing Limited ("the Company") is a private Company, limited by shares and incorporated in England and Wales. Its registered office is Unit Li.417 164/180 Union Street, London, England, SE1 0LH.

This is the first period of account for the Company, covering the period from incorporation on 30 January 2025 to 31 March 2026.

The principal activity was that of a medical recruitment agency.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

2.Accounting policies (continued)

2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

∙the amount of revenue can be measured reliably;

∙it is probable that the Company will receive the consideration due under the contract;

∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and

∙the costs incurred and the costs to complete the contract can be measured reliably.

2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.5

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

2.6

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Page 4

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

2.Accounting policies (continued)

2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment

25%

straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Employees

The average monthly number of employees, including directors, during the period was 9.

Page 5

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

4.	Tangible fixed assets

		Office equipment
		£
	Cost or valuation
	Additions	4,199
	At 31 March 2026	4,199
	Depreciation
	Charge for the period on owned assets	192
	At 31 March 2026	192
	Net book value
	At 31 March 2026	4,007

Debtors

					2026
					£


	Trade debtors	1,530,832
	Amounts owed by group undertakings	1,942
	Other debtors	64,835
	Prepayments and accrued income	67,854
		1,665,463

6.	Cash and cash equivalents
		2026
		£

	Cash at bank and in hand	209,892

Page 6

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

7.	Creditors: Amounts falling due within one year
		2026
		£

	Trade creditors	377,697
	Corporation tax	87,532
	Other taxation and social security	50,893
	Other creditors	1,080,110
	Accruals and deferred income	70,246
		1,666,478

8.	Share capital
		2026
		£

		Allotted, called up and fully paid

		1 Ordinary share of £1.00	1

On incorporation, 1 £1 Ordinary share was issued at par.

9.	Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £6,088. Contributions totalling £9,955 were payable to the fund at the balance sheet date and are included in creditors.

10.	Related party transactions
	At the period end, the Company owed £921,958 to connected companies, and was owed £1,942 by a connnected company. The loans were unsecured and interest-free.

11.	Post balance sheet events

At the period end, the Company owed £916,316 to a connected company. In April 2026, on completion of the sale of that connected company to a third party, the balance was assigned to a director, who also advanced a further £160,000 to the Company in April 2026. The combined balance of £1,076,316 is governed by a loan agreement dated 18 April 2026, as varied by a deed dated 18 May 2026. It is secured by a debenture, repayable on demand, and bears interest at 8% per annum following an initial three-month interest-free period.

Page 7

MSI PHARMA STAFFING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2026

12.	Controlling party

The controlling party is MSI Group Holdings Limited, a company incorporated in England and Wales.

Page 8